Altimmune (ALT) Non Operating Income (2010 - 2026)

Altimmune (ALT) has reported Non Operating Income for 17 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income rose 7.83% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $5.8 million (down 19.73% YoY), while the FY2025 annual figure was $5.7 million, down 29.56% from the prior year.
• Non Operating Income grew to $1.7 million in Q1 2026 per ALT's latest filing, from $1.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at $2.4 million in Q1 2024 and bottomed at $69000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $1.5 million across 5 years, with a median of $1.7 million in 2023.
• Annual changes were most pronounced in 2022 — Non Operating Income soared 2400.0% — and 2025, when it sank 63.14%.
• Altimmune's Non Operating Income stood at $1.4 million in 2022, then jumped by 38.21% to $2.0 million in 2023, then slipped by 14.93% to $1.7 million in 2024, then retreated by 8.96% to $1.5 million in 2025, then rose by 9.51% to $1.7 million in 2026.
• Business Quant data shows ALT's Non Operating Income at $1.7 million in Q1 2026, $1.5 million in Q4 2025, and $1.8 million in Q3 2025.